CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
三线或更后线复发/难治性大 B 细胞淋巴瘤中 epcoritamab 与化学免疫治疗、以 polatuzumab 为基础的方案、以 tafasitamab 为基础的方案或 CAR-T 细胞治疗的治疗结局比较
英文原题：Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma.
查看英文原题
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
对于经过2线治疗后的复发性/难治性（R/R）弥漫性大B细胞淋巴瘤（DLBCL），已有许多治疗方法可供选择，尽管关于这些疗法比较疗效的证据尚不充分。本研究采用逆概率治疗加权，将EPCORE NHL-1试验中epcoritamab的治疗结局，与来自临床实践队列的个体患者数据进行间接比较；这些队列患者接受化学免疫治疗（CIT）及新型疗法（基于polatuzumab的方案、基于tafasitamab的方案和CAR-T 细胞[CAR-T]疗法）用于三线或更晚期R/R大B细胞淋巴瘤（LBCL）和DLBCL的治疗。在该分析中，epcoritamab的缓解率和总生存率显著优于CIT、基于polatuzumab的方案和基于tafasitamab的方案。在R/R LBCL中，epcoritamab与CAR-T 相比，缓解率或生存方面未发现具有统计学显著性的差异。
展开英文摘要原文
Many therapies are available for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after 2 lines of therapy, albeit with scant evidence on the comparative effectiveness of these therapies.
This study used inverse probability of treatment weighting to indirectly compare treatment outcomes of epcoritamab from the EPCORE NHL-1 trial with individual patient data from clinical practice cohorts treated with chemoimmunotherapy (CIT) and novel therapies (polatuzumab-based regimens, tafasitamab-based regimens, and chimeric antigen receptor T-cell [CAR T] therapies) for third-line or later R/R large B-cell lymphoma (LBCL) and DLBCL.
In this analysis, epcoritamab demonstrated significantly better response rates and overall survival rates than CIT, polatuzumab-based regimens, and tafasitamab-based regimens. No statistically significant differences in response rates or survival were found for epcoritamab compared with CAR T in R/R LBCL.
论文信息
- 作者
- Rosenthal A、Munoz J、Jun M、Wang T、Mutebi A、Wang A、Yang S、Osei-Bonsu K
- 单位
- Mayo Clinic, Phoenix, AZ, USA. rosenthal.allison@mayo.edu.United States
- 文献类型
- 对照研究 · 读者来信
- 期刊
- Journal of hematology & oncology2024 Aug 16
- 原文标识
- PubMed 39152509 · DOI 10.1186/s13045-024-01594-x
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →